NL-OMON41377WithdrawnNot Applicable
Detection of cardiac amyloidosis with 18F-florbetaben PET: a proof-of-principle study - Detection of cardiac amyloidosis with 18F-florbetaben PET
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Withdrawn
- Sponsor
- Academisch Medisch Centrum
- Enrollment
- 20
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •Cardiac amyloidosis:
- •1) Defined as histological proven by biopsy of the myocardium
- •2) or if not proven by myocardial biopsy the patient must fulfill all of the following criteria:
- •- Biopsy proven amyloidosis in another organ than the heart
- •- Left ventricular hypertrophy (> 12 mm) in combination with right ventricular hypertrophy (> 5 mm).
- •- Diastolic dysfunction and biatrial dilatation.
- •- Monoclonal protein and bone marrow plasmaceldyscrasie or transthyretin mutation
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Completed
Early Phase 1
PET/MRI Evaluation of Cardiac AmyloidCardiac AmyloidosisNCT03119558Stanford University9
Terminated
Phase 4
The Role of F-18 Florbetapir in the Early Detection of Cardiac AmyloidosisCardiac AmyloidosisNCT03040427The Cleveland Clinic12
Completed
Not Applicable
Assessment of 18F-Florbetaben Whole-body PET for the Detection of Cardiac and Extracardiac Sites of Amyloid DepositsCardiac AmyloidosisNCT03616496Central Hospital, Nancy, France67
Unknown
Not Applicable
The Potential Role of 18F-NaF PET/CT in Diagnosing Cardiac AmyloidosisCardiac AmyloidosisNCT04146480Tel-Aviv Sourasky Medical Center40
Not yet recruiting
Unknown
Screening for cardiac amyloidosis in patients with newly identified conduction diseaseCardiac amylodiosisCardiovascular - Other cardiovascular diseasesACTRN12624000520538Box Hill Hospital220